Why Did ReShape Lifesciences Plunge 10.53% Despite EU MDR Certification?

On June 9, 2025, ReShape Lifesciences experienced a significant drop of 10.53% in pre-market trading, reflecting a notable shift in investor sentiment towards the company.

ReShape Lifesciences has a short interest of 44,000 shares, representing 6.29% of the float. This indicates a level of bearish sentiment among investors, as short selling is often used as a strategy to profit from a decline in a stock's price.

ReShape Lifesciences recently announced that it has achieved EU MDR certification for its entire European product portfolio. This certification is a significant milestone for the company, as it demonstrates compliance with the European Union's Medical Device Regulation (MDR) standards, which are among the most stringent in the world. This achievement is likely to enhance the company's reputation and market position in Europe, potentially leading to increased sales and market share.